APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
28 août 2023 11h00 HE
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...